You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
廣濟藥業(000952.SZ):2020年淨利降14.14%至7464.71萬元 擬10派0.6元
格隆匯 03-23 17:46

格隆匯3月23日丨廣濟藥業(000952.SZ)披露2020年年度報吿,實現營業收入6.88億元,同比下降5.90%;歸屬於上市公司股東的淨利潤7464.71萬元,同比下降14.14%;歸屬於上市公司股東的扣除非經常性損益的淨利潤3864.5萬元,同比下降24.26%;基本每股收益0.2232元。擬向全體股東每10股派發現金紅利0.6元(含税)。

2020年,新冠疫情在全球迅速蔓延,我國經濟增速持續放緩,經濟運行面臨諸多風險和挑戰,國內維生素市場競爭加劇,生產經營環境和市場競爭局勢發生重大而深刻變化;同時醫藥行業延續深化醫改,市場監管日益趨嚴,產業升級加速,醫藥行業面臨新的挑戰和機遇。面對複雜多變的局面,公司精心組織生產,採取了一系列增收節支、降本增效的應對措施,但受宏觀經濟形勢和行業供求關係影響,公司主導產品價格及經營業績較去年同期出現下滑。

2020年度維生素市場行情低迷,主導產品核黃素銷售價格處於市場週期的低價格水平,面對激烈的市場競爭環境,公司堅持“原料為基、製劑聯動、穩健擴張、協調發展”的十六字方針和穩中求進的工作總基調,以產品開發、市場份額、效益優先為目標,以穩質、高產、降成本為主線,以創新和績效為驅動,加強內部管理和資源優化相結合,強化計劃引導,繼續在醫藥原料、新型製劑、多種維生素領域深度耕耘,加強與科研機構研發合作,實現優勢互補、資源共享,提升公司研發實力。同時,積極藉助資本市場通道來加快企業高質量發展,上市20年來非公開發行股份事項首次通過證監會審核,成功募集資金3.64億元,實現了資本市場“零突破”。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account